Search
TAK-754
go.drugbank.com/drugs/DB17850InvestigationalTAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.
Bemnifosbuvir
go.drugbank.com/drugs/DB19050InvestigationalBemnifosbuvir is under investigation in clinical trial NCT05629962 (SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-risk Outpatients With COVID-19).
Categories: Nucleic Acids, Nucleotides, and NucleosidesGuanosine
go.drugbank.com/drugs/DB02857InvestigationalGuanosine can be phosphorylated to become GMP (guanosine monophosphate), cGMP (cyclic guanosine monophosphate), GDP (guanosine diphosphate) and GTP (guanosine triphosphate) which are factors in signal
Categories: Nucleic Acids, Nucleotides, and NucleosidesISIS 14803
go.drugbank.com/drugs/DB05803InvestigationalISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits
Imidocarb
go.drugbank.com/drugs/DB11521ExperimentalVet approvedImidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.
Sulesomab
go.drugbank.com/drugs/DB13976ApprovedMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Categories: Amino Acids, Peptides, and Proteins, Inflammation and Infection DetectionRTA 744
go.drugbank.com/drugs/DB05920InvestigationalRTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. … Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier
AUTO3
go.drugbank.com/drugs/DB17364InvestigationalIt is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.
AZD8630
go.drugbank.com/drugs/DB19397Investigationaland Pharmacodynamics (NCT05110976) … AZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics